Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

149 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Capecitabine/oxaliplatin, a safe and active first-line regimen for older patients with metastatic colorectal cancer: post hoc analysis of a large phase II study.
Twelves CJ, Butts CA, Cassidy J, Conroy T, Braud Fd, Diaz-Rubio E, Tabernero JM, Schoffski P, Figer A, Brunet R, Grossmann J, Sobrero AF, Van Cutsem EJ. Twelves CJ, et al. Among authors: butts ca. Clin Colorectal Cancer. 2005 Jul;5(2):101-7. doi: 10.3816/ccc.2005.n.021. Clin Colorectal Cancer. 2005. PMID: 16098250
Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/folinic acid plus oxaliplatin (FOLFOX-4) as second-line therapy in metastatic colorectal cancer: a randomized phase III noninferiority study.
Rothenberg ML, Cox JV, Butts C, Navarro M, Bang YJ, Goel R, Gollins S, Siu LL, Laguerre S, Cunningham D. Rothenberg ML, et al. Ann Oncol. 2008 Oct;19(10):1720-6. doi: 10.1093/annonc/mdn370. Epub 2008 Jun 10. Ann Oncol. 2008. PMID: 18550577 Free article. Clinical Trial.
Epacadostat plus pembrolizumab versus placebo plus pembrolizumab as first-line treatment for metastatic non-small cell lung cancer with high levels of programmed death-ligand 1: a randomized, double-blind phase 2 study.
Tokito T, Kolesnik O, Sørensen J, Artac M, Quintela ML, Lee JS, Hussein M, Pless M, Paz-Ares L, Leopold L, Daniel J, Munteanu M, Samkari A, Xu L, Butts C. Tokito T, et al. BMC Cancer. 2024 Jul 25;23(Suppl 1):1251. doi: 10.1186/s12885-023-11203-8. BMC Cancer. 2024. PMID: 39054476 Free PMC article. Clinical Trial.
Randomized phase II study of gemcitabine plus cisplatin or carboplatin [corrected], with or without cetuximab, as first-line therapy for patients with advanced or metastatic non small-cell lung cancer.
Butts CA, Bodkin D, Middleman EL, Englund CW, Ellison D, Alam Y, Kreisman H, Graze P, Maher J, Ross HJ, Ellis PM, McNulty W, Kaplan E, Pautret V, Weber MR, Shepherd FA. Butts CA, et al. J Clin Oncol. 2007 Dec 20;25(36):5777-84. doi: 10.1200/JCO.2007.13.0856. J Clin Oncol. 2007. PMID: 18089875 Clinical Trial.
An international, multicenter, randomized phase III study of first-line erlotinib followed by second-line cisplatin/gemcitabine versus first-line cisplatin/gemcitabine followed by second-line erlotinib in advanced non-small-cell lung cancer: treatment rationale and protocol dynamics of the TORCH trial.
Gridelli C, Butts C, Ciardiello F, Feld R, Gallo C, Perrone F. Gridelli C, et al. Clin Lung Cancer. 2008 Jul;9(4):235-8. doi: 10.3816/CLC.2008.n.037. Clin Lung Cancer. 2008. PMID: 18650174 Clinical Trial.
Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial.
Neoptolemos JP, Stocken DD, Bassi C, Ghaneh P, Cunningham D, Goldstein D, Padbury R, Moore MJ, Gallinger S, Mariette C, Wente MN, Izbicki JR, Friess H, Lerch MM, Dervenis C, Oláh A, Butturini G, Doi R, Lind PA, Smith D, Valle JW, Palmer DH, Buckels JA, Thompson J, McKay CJ, Rawcliffe CL, Büchler MW; European Study Group for Pancreatic Cancer. Neoptolemos JP, et al. JAMA. 2010 Sep 8;304(10):1073-81. doi: 10.1001/jama.2010.1275. JAMA. 2010. PMID: 20823433 Clinical Trial.
149 results